How to access Amvuttra from India, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient, or a diaspora family supporting a relative in Chennai, Mumbai, Hyderabad, or Bengaluru, diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Amvuttra (vutrisiran) from their treating neurologist. Amvuttra is FDA-approved for this indication and developed by Alnylam Pharmaceuticals.
This guide explains the legal pathway, the documentation your neurologist prepares, typical timing, how quotes work, and where Reserve Meds fits in.
Ask about Amvuttra in India
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Amvuttra is a subcutaneous small interfering RNA (siRNA) therapy that silences hepatic TTR production. It is administered once every three months by subcutaneous injection, a practical advantage in India, where infusion-chair infrastructure and travel distance to tertiary centres are real constraints for families. Eligibility is anchored in genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy (sensory, motor, or autonomic), and exclusion of confounding diagnoses. Your neurologist will establish baseline neuropathy impairment scoring (NIS or NIS+7), modified body mass index (mBMI), polyneuropathy disability score, and a cardiac workup, ECG, echocardiogram, NT-proBNP, to characterise any ATTR-CM overlap. Amvuttra is given in-clinic by a trained clinician; no infusion suite, no premedication regimen.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Amvuttra legally importable into India?
Yes, through the CDSCO / Drugs Controller General of India (DCGI) personal-use and hospital-sponsored named-patient import frameworks. India has a mature personal-use mechanism that has supported rare-disease access for many years. A registered medical practitioner, or the patient themselves, on personal-use grounds with physician documentation, may request import of a medicine approved by a recognised reference authority such as the US FDA when no clinically equivalent registered alternative exists. hATTR polyneuropathy has limited disease-specific registered options in India, which supports clinical rationale.
How the pathway works, step by step
- Consultation with your treating neurologist. TTR genetic report, neuropathy impairment scoring, and a clinical rationale documenting the absence of equivalent registered alternatives.
- Baseline assessment. NIS/NIS+7, polyneuropathy disability score, mBMI, cardiac workup (ECG, echocardiogram, NT-proBNP), and renal/hepatic panels.
- CDSCO personal-use / named-patient application. The physician or hospital pharmacy files clinical rationale, genetic report, patient identification, and product details.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Amvuttra from authorised distribution under DSCSA.
- Cold-chain shipment. Amvuttra requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging and customs clearance support.
- Arrival and administration. The hospital pharmacy receives the product; the neurology clinic administers the subcutaneous dose and schedules the next quarterly visit.
What documentation your physician needs
- Clinical rationale letter confirming hATTR polyneuropathy and Amvuttra as the indicated therapy
- Verification of Indian medical registration (NMC / state medical council)
- TTR genetic test result from an accredited laboratory
- Baseline NIS/NIS+7 and polyneuropathy disability score
- Cardiac assessment for ATTR-CM overlap
- Planned dosing schedule (every 3 months) and long-term monitoring plan
Reserve Meds provides a physician documentation kit bundling the templates CDSCO reviewers and Indian customs officers typically expect for rare-disease named-patient imports.
Costs and timing
Medicine price: quote on request. Every case gets a written custom quote before you commit. Reserve Meds provides a transparent, itemised delivered quote, covering product, cold-chain logistics, CDSCO documentation handling, customs clearance, and coordination, at the start of intake.
We give you a written timeline estimate for your case before you commit. Subsequent quarterly doses ship on a scheduled cadence once the pathway is established.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: hATTR is autosomal-dominant, and Indian families often coordinate care decisions across generations and continents, a parent in Chennai, a sibling in New Jersey, a cousin in Dubai. Our team coordinates with whichever family members the patient designates and accepts diaspora payment.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and CDSCO / customs review.
- Logistics. Validated cold-chain shipment with customs clearance support.
- Dedicated case lead. A named point of contact for long-term quarterly refills.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO personal-use / named-patient framework with appropriate documentation. See our trust and compliance page.
How is Amvuttra different from Onpattro or Wainua? All three address hATTR polyneuropathy but differ in mechanism and administration. Amvuttra is subcutaneous siRNA given once every three months. Onpattro is intravenous siRNA given every three weeks with a premedication regimen. Wainua is a subcutaneous antisense oligonucleotide given monthly. Your neurologist selects based on the clinical picture, patient preference, and logistics.
Can diaspora family pay directly? Yes. Cross-border payment is common; we issue invoicing that family members in the US, UK, UAE, Canada, Australia, and Singapore can settle directly.
Will insurance cover this? Cash-pay is the default. Some Indian private insurers and diaspora policies consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Recent regulatory and access news for Amvuttra in India
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a Amvuttra-specific notification over the last 12 months as of 2026-06-04. The Drugs Controller General of India has not added Amvuttra to the Approved New Drugs list at cdsco.gov.in Approved-New-Drugs. The National Pharmaceutical Pricing Authority database at nppaindia.nic.in and the Pharmacovigilance Programme of India at ipc.gov.in have not registered Amvuttra-specific signals. Alnylam continues commercial rollout of vutrisiran (subcutaneous RNAi) for hereditary transthyretin amyloidosis with polyneuropathy and ATTR cardiomyopathy. We update this section on each case file at intake; the snapshot date governs.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Frequently asked questions
How can I get Amvuttra in India if it is not approved or available there?
Reserve Meds coordinates US-sourced Amvuttra for patients in India through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for India and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Amvuttra in India through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Amvuttra. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in India, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Amvuttra in India through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Amvuttra to a patient in India?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Amvuttra to your treating physician or hospital pharmacy in India, with appropriate handling for the product.
How long does it take, and what does Amvuttra in India cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Amvuttra in India?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.